In this target trial emulation study, denosumab was found to increase the risk of hypocalcemia requiring emergency treatment as compared with bisphosphonates among women with osteoporosis in the ...

The Food and Drug Administration (FDA) has added a new boxed warning on the denosumab drug label (brand name: Prolia) to alert clinicians to an increased risk for severe hypocalcemia in patients with ...